2.85
0.07 (2.52%)
| Previous Close | 2.78 |
| Open | 2.79 |
| Volume | 2,716,210 |
| Avg. Volume (3M) | 1,466,740 |
| Market Cap | 636,316,608 |
| Price / Book | 1.30 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Diluted EPS (TTM) | -1.40 |
| Total Debt/Equity (MRQ) | 32.85% |
| Current Ratio (MRQ) | 4.47 |
| Operating Cash Flow (TTM) | -227.95 M |
| Levered Free Cash Flow (TTM) | -187.32 M |
| Return on Assets (TTM) | -31.15% |
| Return on Equity (TTM) | -92.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Sana Biotechnology, Inc. | Bearish | Mixed |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.00 |
|
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.63% |
| % Held by Institutions | 92.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Flagship Pioneering Inc. | 30 Sep 2024 | 25,001,856 |
| Crestline Management, Lp | 30 Sep 2024 | 3,085,624 |
| 52 Weeks Range | ||
| Median | 8.00 (180.70%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Nov 2024 | 8.00 (180.70%) | Buy | 2.55 |
| 11 Nov 2024 | 8.00 (180.70%) | Buy | 2.89 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |